BACKGROUND AND AIMS: The complement pathway is an important component of the innate and adaptive immune response. Here we tested the hypothesis that activation of complement is required for development of ethanol-induced fatty liver. METHODS: Wild-type mice and mice lacking the third (C3) or fifth (C5) components of the complement activation pathway, as well as mice lacking decay-accelerating factor (CD55/DAF), a complement regulatory protein, were fed Lieber-DeCarli ethanol-containing diets for 6 weeks or pair-fed control diets. RESULTS: Ethanol feeding to wild-type mice increased C3a in plasma. Wild-type and C5-/- mice fed the ethanol diet developed hepatic steatosis characterized by microvesicular and macrovesicular lipid accumulation and increased triglyceride content. C3-/- mice did not develop steatosis, while CD55/DAF-/- mice accumulated even more hepatic triglyceride after ethanol feeding than wild-type mice. Levels of serum alanine aminotransferase and hepatic tumor necrosis factor alpha, indicators of hepatocyte injury and inflammation, respectively, were increased in wild-type and CD55/DAF-/- mice but not in C5-/- mice after ethanol feeding. In contrast to the protective effect of C3-/- against ethanol-induced steatosis, levels of both alanine aminotransferase and tumor necrosis factor alpha were increased in C3-/- mice after ethanol feeding. CONCLUSIONS: Here we have identified several elements of the complement system as important contributors to ethanol-induced fatty liver. C3 contributed primarily to the accumulation of triglyceride in the liver, whereas C5 was involved in inflammation and injury to hepatocytes. Further, the absence of CD55/DAF exacerbated these responses, suggesting that CD55/DAF serves as a barrier to ethanol-induced fatty liver.
BACKGROUND AND AIMS: The complement pathway is an important component of the innate and adaptive immune response. Here we tested the hypothesis that activation of complement is required for development of ethanol-induced fatty liver. METHODS: Wild-type mice and mice lacking the third (C3) or fifth (C5) components of the complement activation pathway, as well as mice lacking decay-accelerating factor (CD55/DAF), a complement regulatory protein, were fed Lieber-DeCarli ethanol-containing diets for 6 weeks or pair-fed control diets. RESULTS:Ethanol feeding to wild-type mice increased C3a in plasma. Wild-type and C5-/- mice fed the ethanol diet developed hepatic steatosis characterized by microvesicular and macrovesicular lipid accumulation and increased triglyceride content. C3-/- mice did not develop steatosis, while CD55/DAF-/- mice accumulated even more hepatic triglyceride after ethanol feeding than wild-type mice. Levels of serum alanine aminotransferase and hepatic tumor necrosis factor alpha, indicators of hepatocyte injury and inflammation, respectively, were increased in wild-type and CD55/DAF-/- mice but not in C5-/- mice after ethanol feeding. In contrast to the protective effect of C3-/- against ethanol-induced steatosis, levels of both alanine aminotransferase and tumornecrosis factor alpha were increased in C3-/- mice after ethanol feeding. CONCLUSIONS: Here we have identified several elements of the complement system as important contributors to ethanol-induced fatty liver. C3 contributed primarily to the accumulation of triglyceride in the liver, whereas C5 was involved in inflammation and injury to hepatocytes. Further, the absence of CD55/DAF exacerbated these responses, suggesting that CD55/DAF serves as a barrier to ethanol-induced fatty liver.
Authors: Eric A Albrecht; Arul M Chinnaiyan; Sooryanarayana Varambally; Chandan Kumar-Sinha; Terrence R Barrette; J Vidya Sarma; Peter A Ward Journal: Am J Pathol Date: 2004-03 Impact factor: 4.307
Authors: Maciej M Markiewski; Dimitrios Mastellos; Ruxandra Tudoran; Robert A DeAngelis; Christoph W Strey; Silvia Franchini; Rick A Wetsel; Anna Erdei; John D Lambris Journal: J Immunol Date: 2004-07-15 Impact factor: 5.422
Authors: Stephen E McKim; Erwin Gäbele; Fuyumi Isayama; Jason C Lambert; Lindsay M Tucker; Michael D Wheeler; Henry D Connor; Ronald P Mason; Mark A Doll; David W Hein; Gavin E Arteel Journal: Gastroenterology Date: 2003-12 Impact factor: 22.682
Authors: Utpal B Pajvani; Meredith Hawkins; Terry P Combs; Michael W Rajala; Tom Doebber; Joel P Berger; John A Wagner; Margaret Wu; Annemie Knopps; Anny H Xiang; Kristina M Utzschneider; Steven E Kahn; Jerrold M Olefsky; Thomas A Buchanan; Philipp E Scherer Journal: J Biol Chem Date: 2003-12-29 Impact factor: 5.157
Authors: Christoph W Strey; Maciej Markiewski; Dimitrios Mastellos; Ruxandra Tudoran; Lynn A Spruce; Linda E Greenbaum; John D Lambris Journal: J Exp Med Date: 2003-09-15 Impact factor: 14.307
Authors: Mark A Barnes; Megan R McMullen; Sanjoy Roychowdhury; Nabil Z Madhun; Kathryn Niese; Mitchell A Olman; Abram B Stavitsky; Richard Bucala; Laura E Nagy Journal: J Leukoc Biol Date: 2014-11-14 Impact factor: 4.962
Authors: Palash Mandal; Sanjoy Roychowdhury; Pil-Hoon Park; Brian T Pratt; Thierry Roger; Laura E Nagy Journal: J Immunol Date: 2010-09-22 Impact factor: 5.422
Authors: Raymond J Langley; Neerad C Mishra; Juan Carlos Peña-Philippides; Brandon J Rice; Jean-Clare Seagrave; Shashi P Singh; Mohan L Sopori Journal: J Toxicol Environ Health A Date: 2011
Authors: Xiaocong Chen; Becky M Sebastian; Hui Tang; Megan M McMullen; Armend Axhemi; Donald W Jacobsen; Laura E Nagy Journal: Hepatology Date: 2009-05 Impact factor: 17.425